Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORY-1: Phase III randomized trial of IBI362 in overweight or obese adults in China
CTR20222567Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2022
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Overweight and obesity comparing IBI362 with Placebo (2 arms). Primary endpoints: Percent change in body weight from baseline at week 32 and Proportion of subjects with ≥5% body weight loss from baseline at week 32. Started Oct 2022; status: completed.
02
Drugs
mazdutide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20222567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222567.